Xeltis
Cardiovascular Devices
$124.7Mtotal raised · 6 rounds on record
2open roles
$22.1Mlatest round · Venture round · Jul 2026 · 3 mo ago
3backers · Kurma Partners, Vi Partners
Overview
Xeltis is an international medical technology company developing vascular and valve implants that transform into living blood vessels through the body's own tissue formation. Its aXess vascular access implant is CE marked, and its vacancies include sales, cleanroom, manufacturing, supply chain and research and development roles. The company is headquartered in Eindhoven, Netherlands.
Funding and backers
Total raised
$124.7M
6 rounds on record
Latest round
$22.1M
Venture round · Jul 2026 · 3 mo ago
Team
51-200
employees, estimated range
Hiring now
4
open roles
Grants
$3.9M
3 grants · CORDIS
Backers
3
Kurma Partners, Vi Partners
The money's age
Fresh money
3 months since the last round · hiring slowed
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 28
Raised a round Venture round $22.1M
Apr 21
Launched Xeltis releases groundbreaking new 12-month EU pivotal data for aXess demonstrating the transformative potential in hemodialysis treatment · xeltis.com
Apr 21
Certified Xeltis receives CE mark for aXess, its aXess hemodialysis conduit, as it moves to commercialization · manilatimes.net
Dec 2, 2025
Raised a round Venture round $54M
Jul 23, 2024
New executive Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs · PRNewswire
Dec 1, 2022
Won a grant $2.7M · CORDIS
Jan 1, 2021
Won a grant $691k · CORDIS
Nov 14, 2017
Raised a round Series C $48.6M
Nov 1, 2017
Won a grant $479k · CORDIS
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2026 | $22.1M | — | xeltis.com |
| Venture round | Dec 2025 | $54M | — | xeltis.com |
| Grant | Dec 2022 | $2.7M | — | CORDIS |
| Grant | Jan 2021 | $691k | — | CORDIS |
| Series C | Nov 2017 | $48.6M | — | medindia.net |
| Grant | Nov 2017 | $479k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Kurma Partners 
Vi Partners 
Ysios Capital Investors in similar startupsfunds that back the companies most like this one
backs Pathfinder Medical
backs Capstan Medical
Similar startupsby what they do, their industry and backers
Pathfinder Medical is developing a novel electronic guidance system that will enable clinicians to connect blood vessels in a minimally…
Accelerating the development of life-changing technologies to bring more care to more patients suffering from stroke and other devastating…
Discover SonoStik: the single-handed vascular access device optimized for ultrasound-guided peripheral IV procedures.
ACES® from Pleural Dynamics is the first FDA-cleared implant designed for recurrent pleural effusions. Continuous relief without external…
Capstan Medical develops robotically delivered heart valve implants for minimally invasive structural heart repair. Its system combines a…
Capcyte provides bioactive surface treatments for better cardiovascular implants and cell culture devices.
Jobs
≈ $60k – $120k per year (Estimated) · In office · Full-Time · Master's Degree · Eindhoven
GMP
MedTech
Verification & Validation
Apply
Apply
Growth
Hiring Momentum
32/100
Slowing
Open positions
4
0 opened / 1 closed in 30 days
Median time-to-fill
78 days
faster than 15% of the market
ATS activity
Every ~9 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
33% ▼
Sales
33% ▲
Industrial Engineering
33% ▼
Activity Timeline
Added Verification & Validation to stack
Oct 2026
Added Statistical Process Control to stack
Oct 2026
Added GMP to stack
Oct 2026
Added Microsoft Office to stack
Sep 2026
Financials
Total raised
$128.6M
Latest round
Venture - Series Unknown
Funding rounds
6
Tech stack
Technologies named in job postings at Xeltis over the last 12 months, by layer, with the share of postings for each.
Technologies in use
4
Postings analysed
3
Stack modernity
58/100
Developer tools
SolidWorks
Practices & domains
GMP
Statistical Process Control
Verification & Validation
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Xeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launch
New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis' next phase of
Read more
Report
Xeltis makes first commercial implant of aXess, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess, bringing it into routine clinical practiceBuilds on CE mark approval in record time, underpi...
Read more
Report
Xeltis makes first commercial implant of aXess, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data Introduces a first-of-its-kind living vascular access solution for pat
Read more
Report
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice 50% of target enrollment reached across 20 sites in the United States EINDHOVEN,
Read more
Report
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess demonstrating the transformative potential in hemodialysis treatment
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1
Read more
Report
Xeltis receives CE mark for aXess, its aXess hemodialysis conduit , as it moves to commercialization
CE mark awarded for aXess at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercialization aXess reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN
Read more
Report
Xeltis receives CE mark for aXess, its aXess hemodialysis conduit, as it moves to commercialization
CE mark awarded for aXess at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercializationaXess reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN,
Read more
Report
Xeltis receives CE mark for aXess, its aXess hemodialysis conduit, as it moves to commercialization
Read more
Report
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m €10m investment from existing shareholders including EQT Life Sciences (EQT) and Invest-NL Follows the announcement of excellent
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Eindhoven
Eindhoven
Netherlands
HQ
3 open roles 5 posted in 90 days 33% engineering 50-200 est. staff
hires for Backend, Customer Success, Semiconductors
High Tech Campus 7